Table 4.
Results of the stepwise logistic regression analysis to find factors associated with different promoters for switch to rivastigmine patches
| Odds ratio | P value | |||
|---|---|---|---|---|
|
|
||||
| Point estimate | Low 95% CI | Upper 95% CI | ||
| Physician as promoter of switch | ||||
| Previous treatment for AD | ||||
| Donepezil versus rivastigmine | 0.595 | 0.393 | 0.902 | 0.0145 |
| Galantamine versus rivastigmine | 1.277 | 0.694 | 2.348 | 0.4318 |
| Other versus rivastigmine | 1.824 | 0.415 | 8.014 | 0.4262 |
| Patient as promoter of switch | ||||
| MMSE score | 1.163 | 1.078 | 1.255 | 0.0001 |
| Number of concomitant diseases | 1.438 | 1.146 | 1.805 | 0.0017 |
| Number of concomitant treatments | 0.661 | 0.528 | 0.828 | 0.0003 |
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; MMSE, Mini-Mental State Examination.